{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:54:19Z","timestamp":1787698459372,"version":"build-2784847793"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Control of prolactin excess is associated with the improvement in gluco-insulinemic and lipid profile. The current study aimed at investigating the effects of pituitary surgery and medical therapy with high dose cabergoline (\u22652mg\/week) on metabolic profile in patients with prolactinoma resistant to cabergoline conventional doses (&amp;lt;2mg\/week).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Thirty-four patients (22 men, 12 women, aged 33.9 \u00b1 12.5 years) with prolactinoma (4 microadenomas and 30 macroadenomas) were included in the present study. Among them 17 (50%) received pituitary surgery (PS, Group1) and 17 (50%) medical therapy with high dose cabergoline (Group 2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the whole patient cohort, anthropometric (weight, BMI) and biochemical (fasting glucose and insulin, triglycerides, total, HDL and LDL-cholesterol, HOMA-IR, HOMA-\u03b2 and ISI0) parameters were evaluated before and within 12 months after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In Group 1, prolactin (p=0.002), total cholesterol (p=0.012), and triglycerides (p=0.030) significantly decreased after pituitary surgery compared to the baseline. Prolactin significantly correlated with fasting glucose (r=0.056, p=0.025). In Group 2, fasting insulin (p=0.033), HOMA-\u03b2 (p=0.011) and ISI0 (p=0.011) significantly improved compared to baseline. Postoperative cabergoline dose significantly correlated with \u0394fasting glucose (r=-0.556, p=0.039) and \u0394LDL cholesterol (r=- 0.521, p=0.046), and was the best predictor of \u0394LDL cholesterol (r\n                      <jats:sup>2 =<\/jats:sup>\n                      0.59, p=0.002) in Group 1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The rapid decrease in PRL levels induced by PS might improve lipid metabolism, whereas HD-CAB might exert a beneficial impact on both insulin secretion and peripheral sensitivity, thus inducing a global metabolic improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2021.769744","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T14:45:51Z","timestamp":1638369951000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment"],"prefix":"10.3389","volume":"12","author":[{"given":"Rosa","family":"Pirchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata S.","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Solari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Arnesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Negri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi M.","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cappabianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/17446651.2018.1434412","article-title":"The Effects of Hyperprolactinemia and Its Control on Metabolic Diseases","volume":"13","author":"Auriemma","year":"2018","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e12888","DOI":"10.1111\/jne.12888","article-title":"Metabolic Functions of Prolactin: Physiological and Pathological Aspects","volume":"32","author":"Lopez-Vicchi","year":"2020","journal-title":"J Neuroendocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2020.01.004","article-title":"Time for a New Perspective on Prolactin in Metabolism","volume":"31","author":"Macotela","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2006.02.005","article-title":"Focus on Prolactin as a Metabolic Hormone","volume":"17","author":"Ben-Jonathan","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1530\/eje.0.1470077","article-title":"Dopaminergic Tone and Obesity: An Insight From Prolactinomas Treated With Bromocriptine","volume":"147","author":"Doknic","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1480325","article-title":"Gender Differences in the Prevalence, Clinical Features and Response to Cabergoline in Hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000054522","article-title":"Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone,Body Weight Gain, and Hyperglycemia in Ob\/Ob Mice","volume":"71","author":"Bina","year":"2000","journal-title":"Neuroendocrinology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00327","article-title":"Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas","volume":"10","author":"Auriemma","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb00541.x","article-title":"Peripheral Glucose Metabolism in Human Hyperprolactinaemia","volume":"43","author":"Foss","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1490187","article-title":"Endothelial Function, Insulin Sensitivity and Inflammatory Markers in Hyperprolactinemic Premenopausal Women","volume":"149","author":"Yavuz","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/endo.137.12.8940406","article-title":"Prolactin Receptor Expression During Adipocyte Differentiation of Bone Marrow Stroma","volume":"137","author":"McAveney","year":"1996","journal-title":"Endocrinology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1172","article-title":"Prolactin Release by Adipose Explants, Primary Adipocytes, and LS14 Adipocytes","volume":"93","author":"Hugo","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505560200","article-title":"Dopamine D2-Like Receptors Are Expressed in Pancreatic Beta Cells and Mediate Inhibition of Insulin Secretion","volume":"280","author":"Rub\u00ed","year":"2005","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e25537","DOI":"10.1371\/journal.pone.0025537","article-title":"Dopamine Receptors in Human Adipocytes: Expression and Functions","volume":"6","author":"Borcherding","year":"2011","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1472-6823-10-10","article-title":"Prolactinomas, Cushing\u2019s Disease and Acromegaly: Debating the Role of Medical Therapy for Secretory Pituitary Adenomas","author":"Biller","year":"2010","journal-title":"BMC Endocr Disord"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Endocrine Society. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptine: A Novel Approach to the Treatment of Type 2 Diabetes","volume":"23","author":"Pijl","year":"2000","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e4818","DOI":"10.1097\/MD.0000000000004818","article-title":"Effects of Cabergoline on Blood Glucose Levels in Type 2 Diabetic Patients: A Double-Blind Controlled Clinical Trial","volume":"95","author":"Bahar","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000357810","article-title":"Effect of Cabergoline on Metabolism in Prolactinomas","volume":"98","author":"Auriemma","year":"2013","journal-title":"Neuroendocrinology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12204","article-title":"Higher Doses of Cabergoline Further Improve Metabolic Parameters in Patients With Prolactinoma Regardless of the Degree of Reduction in Prolactin Levels","volume":"79","author":"Ciresi","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11102-010-0277-9","article-title":"Insulin Sensitivity and Lipid Profile in Prolactinoma Patients Before and After Normalization of Prolactin by Dopamine Agonist Therapy","volume":"14","author":"Berinder","year":"2011","journal-title":"Pituitary"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345636","article-title":"Body Fat in Men With Prolactinomas","volume":"31","author":"Naliato","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000371851","article-title":"Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients With Prolactinomas","volume":"101","author":"Auriemma","year":"2015","journal-title":"Neuroendocrinology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1982.tb00731.x","article-title":"Serum Lipids,Postheparin Plasma Lipase Activities and Glucose Tolerance in Patients With Prolactinoma","volume":"16","author":"Pelkonen","year":"1982","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00038","article-title":"Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas. B","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J Endocr Soc"},{"key":"B27","article-title":"Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part. 1","volume-title":"Diagnosis and Classification of Diabetes Mellitus","author":"Alberti","year":""},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883","article-title":"Homeostasis Model Assessment: Insulin Resistance and \u03b2-Cell Function From Fasting Plasma Glucose and Insulin in Man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(99)00116-3","article-title":"Validation of the Insulin Sensitivity Index (ISI 0,120 ): Comparison With Other Measures","volume":"47","author":"Gutt","year":"2000","journal-title":"Diabetes Res Clin Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3039","article-title":"Colao a. Results of a Single-Center Observational 10-Year Survey Study on Recurrence of a Hyperproactinemia After Pregnancy and Lactation","volume":"98","author":"Auriemma","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0231","article-title":"Safety of Long-Term Treatment With Cabergoline on Cardiac Valve Disease in Patients With Prolactinomas","volume":"169","author":"Auriemma","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02469.x","article-title":"The Influences of Hyperprolactinemia and Obesity on Cardiovascular Risk Markers: Effects of Cabergoline Therapy","volume":"64","author":"Serri","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.150","article-title":"BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists","volume":"19","author":"Dos Santos Silva","year":"2011","journal-title":"Obes (Silver Spring)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/BF01721038","article-title":"Chronic Hyperprolactinemia and Plasma Lipids in Women","volume":"65","author":"Heshmati","year":"1987","journal-title":"Klin Wochenschr"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03752.x","article-title":"Blood Coagulation, Fibrinolysis and Lipid Profile in Patients With Prolactinoma","volume":"73","author":"Erem","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B36","article-title":"Decreased Apolipoprotein Levels in Women With Hyperprolactinemia Related to Increased Estradiol Level: Effect of Hepatic Lesion","volume":"19","author":"Oravec","year":"1985","journal-title":"Endocrinol Exp"},{"key":"B37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12902-021-00733-6","article-title":"Adverse Body Composition and Lipid Parameters in Patients With Prolactinoma: A Case-Control Study. BMC","volume":"21","author":"Posawetz","year":"2021","journal-title":"Endocr Disord"},{"key":"B38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13098-015-0094-4","article-title":"Metabolic Abnormalities in Patients With Prolactinoma: Response to Treatment With Cabergoline","author":"Pala","year":"2015","journal-title":"Diabetol Metab Syndr"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01304.x","article-title":"Bromocriptine: Old Drug, New Formulation and New Indication","volume":"12","author":"Holt","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-4889(98)00092-5","article-title":"Dopamine Agonist Treatment Ameliorates Hyperglycemia, Hyperlipidemia, and the Elevated Basal Insulin Release From Islets of Ob\/Ob Mice","volume":"1405","author":"Liang","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"B41","doi-asserted-by":"publisher","first-page":"100258","DOI":"10.1016\/j.jcte.2021.100258","article-title":"Impact of Primary Medical or Surgical Therapy on Prolactinoma Patients' BMI and Metabolic Profile Over the Long-Term","volume":"24","author":"Andereggen","year":"2021","journal-title":"J Clin Transl Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.769744\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T14:45:54Z","timestamp":1638369954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.769744\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":41,"alternative-id":["10.3389\/fendo.2021.769744"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.769744","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"article-number":"769744"}}